Physician profile
David Becker
NPI 1629151477
$6,715.58
in general payments reported to CMS, 2019-2025
39 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $790 · 2020: $334 · 2021: $299 · 2022: $716 · 2023: $1,637 · 2024: $1,276 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,451 · Education: $111 · Entertainment: $13.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,450.54 |
| Education | $111.04 |
| Entertainment | $13.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,605.74 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,102.95 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $851.01 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.37 | 2019-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $335.30 | 2019-2025 | |
| Madrigal Pharmaceuticals | $310.46 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $300.29 | 2019-2025 | |
| Celgene Corporation | $190.35 | 2022-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $185.91 | 2024-2025 | Voquezna |
| Celltrion USA INC. | $172.86 | 2024-2025 | Zymfentra, Vegzelma |
| Ironwood Pharmaceuticals, INC | $129.43 | 2019-2023 | Linzess |
| Portola Pharmaceuticals, LLC | $126.65 | 2019 | |
| Aimmune Therapeutics, INC. | $109.35 | 2024-2025 | Zenpep |
| Lilly USA, LLC | $80.90 | 2023-2025 | Omvoh |
| Novo Nordisk INC | $78.46 | 2025 | Wegovy |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.